Predicting recurrence of Stage IA lung adenocarcinoma using ctDNA whole genome mutational signatures.
A blood test can detect early lung cancer recurrence months before imaging shows it, helping catch returning disease when treatment options are broadest.
Tumor-informed ctDNA whole-genome sequencing predicted recurrence in Stage IA NSCLC with 0.75 sensitivity and 0.83 specificity, with a median 16.7-month lead time over clinical/imaging detection; also distinguished second primary from recurrence in histologically challenging cases. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- prospective diagnostic cohort (n=42, tumor-informed WGS ctDNA)
- Category
- early_cancer_detection
- Maturity
- Validated
- Journal
- J Mol Diagn
Why it surfaced
Novel application of whole-genome ctDNA surveillance to the earliest-stage NSCLC, where recurrence risk is underappreciated and no validated liquid biopsy approach currently exists. High novelty (tumor-informed WGS with AI mutational signatures) and direct unmet clinical need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.